Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMDFree Report) in a research note issued to investors on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Trading Down 3.8 %

Shares of GLMD opened at $0.35 on Tuesday. The firm has a market cap of $1.75 million, a PE ratio of -0.14 and a beta of 0.80. Galmed Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $5.47. The stock has a fifty day moving average price of $0.38 and a 200-day moving average price of $0.38.

Galmed Pharmaceuticals (NASDAQ:GLMDGet Free Report) last issued its earnings results on Thursday, April 4th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter.

About Galmed Pharmaceuticals

(Get Free Report)

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.

See Also

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.